Electra Therapeutics (ETRA) stock

Precision medicines , market cap $581M

Precision medicines

Market cap $581M

$8.37

-3.90%

As of Monday's close · Live for Pro members at the open

Quality Score

-1

Poor

In its industry

#150of 291

Biotech

Checks firing

1of 14

Trending down

From its high

-46.0%

No 200-day yet

ETRA's Quality Score was unchanged on Mon, Oct 26, at -1.

New listing, trading since Sep 18, 2026. 27 trading days so far, so 5 of the 14 chart checks wait for more history.

Follow ETRA's trial news. Pro members can get an alert when Electra Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ETRA files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on ETRA

Key facts on ETRA
Holding it back	Moves 12.1% a day with no recent filing behind it
Latest filing	424B4, Sep 18 Raised $350M in a sale of shares, about 60% of its market value

ETRA in the news

TodayNo story names it yet.

ETRA catalysts

Coming up

1 past catalyst since 2026, with sizes and sources, for Pro members.Get in free →

What's next for ETRA

Its trials

A trial underway: ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)Phase 2/3 · Recruiting · 156 people · main data estimated Mar 2028 · NCT05416307

1 more trial, 1 filing, for Pro members.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Carl L. Gordon bought 1,333,333 shares on Sep 21. 1 more insider trade this year.

From Form 4: open-market buys and sales only.

Get an alert when Quehuong Dong buys or sells

For Pro members: every trade, and Quehuong Dong’s 2 filings and quotes.

Get an alert when ETRA files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 15 daysANDA decisionIn 15 days · ANDA decisionNRXPNRX PharmaceuticalsPreservative-free ketamineNRXPNRX Pharmaceuticals · $104MPreservative-free ketamineA generic, under FDA review (GDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $356MDeramiocelFDA decision due (PDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $933MMolgramostimFDA decision due (PDUFA)

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

Why ETRA scores -1

PoorTrending down, 1 of 14 chart checks firingWhat the Quality Score means

+1Chart checks 1 of 14 firing right now, one point each
−2Volatility moves 12.1% a day with no recent filing to back itA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

No effect today: Long-term trend, Run-up, Size, Profit, Growth, Dilution, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on ETRA and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 9:21 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when ETRA's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on ETRA and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

ETRA has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on ETRA, and all 14 on every stock.Get in free →

The deep dive on ETRA

What it does and how it makes money1 findingFor Pro members1 finding on what ETRA does and how it makes money, for Pro members
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades ETRA, for Pro members

2 more findings on ETRA, each with its source, for Pro membersGet in free →

How ETRA ranks in Biotech

ETRA is #150 of 291 by Quality Score.

How ETRA ranks in Biotech
1	HALOHalozyme Therapeutics	9/14	21
2	AMRXAmneal Pharmaceuticals	9/14	20
3	RIGLRigel Pharmaceuticals	9/14	19
	EPRXEupraxia Pharmaceuticals		Open for its score
	ETONEton Pharmaceutcials		Open for its score
	EWTXEdgewise Therapeutics		Open for its score
	EXELExelixis		Open for its score
150	ETRAElectra Therapeutics	1/14	-1

ETRA share count over time

Offerings, shelves, and splits of ETRA, from its filings
From its filings	Filed
Raised $350M in a sale of shares, about 60% of its market value	Sep 18, 2026
Registered shares for sale (S-1)	Aug 28, 2026

ETRA's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Quehuong DongPresident & CEO
Gary S. KoeChief Technical Officer
Graham ParryChief Scientific Officer
Nancy StaglianoDirector

See insider trades by person

About Electra Therapeutics

Electra Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer.

electra-therapeutics.com

Listed on Nasdaq on Sep 18, 2026, and is 44% below its $15 offer price now. Its IPO filing and first days

ETRA's score card

Electra Therapeutics (ETRA): Quality Score -1, Poor, #150 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn ETRA's score around: 3 things
1 more filing explained, a plain line each
Real-⁠time prices, no delay

See ETRA's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Oct 26, 2026: ETRA's Quality Score is -1 (Poor), #150 of 291 in Biotech.

Is ETRA a good stock to buy? What its Quality Score says

ETRA scores -1 today, which Breakaway calls Poor. It is #150 of 291 in Biotech by Quality Score, with 1 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ETRA's Quality Score?

ETRA scores -1 today, which Breakaway calls Poor (below zero). That is #150 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ETRA's -1.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.